State-of-the-art preclinical testing of the OMEGA
atrial fibrillation
closure
device
left atrial appendage
preclinical testing
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
01 06 2021
01 06 2021
Historique:
revised:
14
09
2020
received:
12
07
2020
accepted:
02
10
2020
pubmed:
10
10
2020
medline:
12
10
2021
entrez:
9
10
2020
Statut:
ppublish
Résumé
This study aimed to present a new approach of thorough preclinical testing of a novel left atrial appendage (LAA) occluder device. The development of a safe and effective LAA occluder has been shown to be challenging. The novel OMEGATM LAA occluder (Eclipse Medical, Ireland) was tested in a porcine model and three-dimensional (3D) human LAA models - this as a prelude to its first-in-human use. In a first series of in-vivo experiments, the OMEGATM LAA occluder was shown to have a satisfactory device biocompatibility in a porcine model. The design of the OMEGATM device was further refined and optimized following three more series of in-vivo experiments. The second generation OMEGATM device was designed with thinner wires, leading to a profile reduction. Based on in-vitro testing of different OMEGATM device sizes implanted at different depths in human three-dimensional (3D) LAA models, it could be determined that (1) the landing zone should be measured at a median depth of 12 mm from the LAA ostium; (2) the distal self-retaining inverted cup should have 10%-25% compression to minimize device embolization risk; and (3) the disc should be slightly inverted, i.e. pulled into the LAA, to promote complete LAA occlusion. The combined in-vivo and in-vitro testing resulted in an optimized pre-procedural planning of the first-in-human case treated with the OMEGATM device. This series of carefully planned in-vivo and in-vitro experiments allowed demonstration of the safety and efficacy of the OMEGATM LAA occluder. This approach of thorough preclinical testing of medical devices may reduce the risk of complications in first-in-human cases and may become the standard approach for device development and preclinical testing in the future.
Sections du résumé
OBJECTIVES
This study aimed to present a new approach of thorough preclinical testing of a novel left atrial appendage (LAA) occluder device.
BACKGROUND
The development of a safe and effective LAA occluder has been shown to be challenging.
METHODS
The novel OMEGATM LAA occluder (Eclipse Medical, Ireland) was tested in a porcine model and three-dimensional (3D) human LAA models - this as a prelude to its first-in-human use.
RESULTS
In a first series of in-vivo experiments, the OMEGATM LAA occluder was shown to have a satisfactory device biocompatibility in a porcine model. The design of the OMEGATM device was further refined and optimized following three more series of in-vivo experiments. The second generation OMEGATM device was designed with thinner wires, leading to a profile reduction. Based on in-vitro testing of different OMEGATM device sizes implanted at different depths in human three-dimensional (3D) LAA models, it could be determined that (1) the landing zone should be measured at a median depth of 12 mm from the LAA ostium; (2) the distal self-retaining inverted cup should have 10%-25% compression to minimize device embolization risk; and (3) the disc should be slightly inverted, i.e. pulled into the LAA, to promote complete LAA occlusion. The combined in-vivo and in-vitro testing resulted in an optimized pre-procedural planning of the first-in-human case treated with the OMEGATM device.
CONCLUSIONS
This series of carefully planned in-vivo and in-vitro experiments allowed demonstration of the safety and efficacy of the OMEGATM LAA occluder. This approach of thorough preclinical testing of medical devices may reduce the risk of complications in first-in-human cases and may become the standard approach for device development and preclinical testing in the future.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E1011-E1018Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Onalan O, Crystal E. Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atrial fibrillation. Stroke. 2007;38(2):624-630.
Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61(2):755-759.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139-1151.
Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962.
Reddy VY, Doshi SK, Sievert H, PROTECT AF Investigators, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-year follow-up of the PROTECT AF (watchman left atrial appendage system for embolic protection in patients with atrial fibrillation) trial. Circulation. 2013;127(6):720-729.
Reddy VY, Doshi SK, Kar S, et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol. 2017;70(24):2964-2975.
Boersma LV, Ince H, Kische S, et al. Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-year follow-up outcome data of the EWOLUTION trial. Heart Rhythm. 2017;14(9):1302-1308.
Hildick-Smith D, Landmesser U, Camm AJ, et al. Left atrial appendage occlusion with the Amplatzer™ amulet™ device: full results of the prospective global observational study. Eur Heart J. 2020;41(30):2894-2901. https://doi.org/10.1093/eurheartj/ehaa169.
De Backer O, Arnous S, Ihlemann N, et al. Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation: an update. Open Heart. 2014;1(1):e000020. https://doi.org/10.1136/openhrt-2013-000020.
Lairakdomrong K, Srimahachota S, Lertsapcharoen P, et al. Clinical results of large secundum atrial septal defect closure in adult using percutaneous transcatheter cocoon atrial septal occluder. J Med Assoc Thai. 2013;96(9):1127-1134.
Lertsapcharoen P, Khongphatthanayothin A, La-orkhun V, Supachokchaiwattana P, Charoonrut P. Self-expanding nanoplatinum-coated nitinol devices for atrial septal defect and patent ductus arteriosus closure: a swine model. Indian Heart J. 2006;58(4):315-320.
Thanopoulos BD, Biasco L, Dardas P, et al. Catheter closure of atrial septal defects using the cocoon septal occluder: preliminary results of a European multicenter study. Int J Cardiol. 2014;177(2):418-422.
Crick SJ, Sheppard MN, Ho SY, Gebstein L, Anderson RH. Anatomy of the pig heart: comparisons with normal human cardiac structure. J Anat. 1998;193:105-119.
Schwartz RS, Holmes DR, Van Tassel RA, et al. Left atrial appendage obliteration: mechanisms of healing and intracardiac integration. JACC Cardiovasc Interv. 2010;3:870-877.
Kar S, Hou D, Jones R, et al. Impact of watchman and Amplatzer devices on left atrial appendage adjacent structures and healing response in a canine model. JACC Cardiovasc Interv. 2014;7:801-809.
Kim JS, Lee SG, Bong SK, et al. Preclinical assessment of a modified Occlutech left atrial appendage closure device in a canine model. Int J Cardiol. 2016;221:413-418.
Bavo AM, Wilkins BT, Garot P, et al. Validation of a computational model aiming to optimize preprocedural planning in percutaneous left atrial appendage closure. Cardiovasc Comput Tomogr. 2020;14:149-154.